EPZMライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 1月 1970 @ 09:00):

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States...

Stats
本日の出来高	0.00
平均出来高	4.18M
時価総額	0.00
EPS	$-0.210 ( 2022-08-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.704
ATR14	$0.0490 (3.33%)

Insider Trading

Date	Person	Action	Amount	type
2022-08-12	Giordano Michael F	Sell	8 994	Common Stock, par value $0.0001
2022-08-12	Goldfischer Carl	Sell	13 060	Common Stock, par value $0.0001
2022-08-12	Goldfischer Carl	Sell	8 994	Common Stock, par value $0.0001
2022-08-12	Goldfischer Carl	Sell	3 380 951	Common Stock, par value $0.0001
2022-08-12	Conroy Kevin T	Sell	53 324	Common Stock, par value $0.0001

INSIDER POWER
-89.01
Last 98 transactions
Buy: 31 679 726 \| Sell: 42 571 145

ボリューム相関

長: 0.22 (neutral)

短: -0.56 (weak negative)

Signal:(61.298) Neutral

Epizyme Inc 相関

10 最も正の相関
APOP	0.959
RMRM	0.951
MEIP	0.933
PCVX	0.93
NNOX	0.927
RAPT	0.927
NERV	0.926
TYHT	0.925
CVGI	0.922
PRTA	0.921

10 最も負の相関
TWKS	-0.955
SMSI	-0.925
INFI	-0.922
UPLD	-0.921
OM	-0.92
DTEA	-0.919
VNET	-0.916
EYE	-0.913
SBBP	-0.913
REPL	-0.912

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Epizyme Inc 相関 - 通貨/商品

0.43
( neutral )

0.61
( weak )

0.00
( neutral )

0.58
( weak )

0.71
( moderate )

-0.45
( neutral )

Epizyme Inc 財務諸表

Annual	2021
収益:	$37.43M
総利益:	$26.93M (71.95 %)
EPS:	$-2.45

FY	2021
収益:	$37.43M
総利益:	$26.93M (71.95 %)
EPS:	$-2.45

FY	2020
収益:	$15.76M
総利益:	$10.70M (67.85 %)
EPS:	$-2.29

FY	2019
収益:	$23.80M
総利益:	$0.00 (0.00 %)
EPS:	$-1.930

Financial Reports:

No articles found.

Epizyme Inc

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..